Exscientia

Recursion is a technology-driven drug discovery company that uses artificial intelligence to analyze cellular images and decode biological data. Founded over a decade ago, the company aims to reduce the high failure rate of traditional drug discovery by training AI to understand cellular disruptions that cause disease. The Recursion OS platform supports the development of potential first-in-class and best-in-class treatments for conditions with high unmet need, including aggressive cancers and rare diseases. Its pipeline includes programs in oncology—covering advanced solid tumors, lymphomas, B-cell malignancies, and hematology oncology—as well as rare diseases like familial adenomatous polyposis and hypophosphatasia. The company reports improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical averages. Recursion also engages in strategic partnerships to accelerate the discovery of new medicines. The platform is designed for researchers and pharmaceutical partners seeking to bring better medicines to patients faster through data-driven insights and precision design.